PEA

Speaker 1...So, let's talk about Palmitoylethanolamide, or PEA. It's an endogenous anti-inflammatory lipid, part of the cannabinoid system, often used for pain relief.

Speaker 2Right. And for many, it provides genuine relief, which is important because we know unrelieved chronic pain can actually accelerate biological aging. A study in *GeroScience* 2025, for example, noted that painful diabetic neuropathy is linked to accelerated epigenetic aging and telomere shortening compared to painless neuropathy.

Speaker 1That’s a crucial point. Managing pain is vital. But the longevity thesis for PEA itself gets interesting. The question isn't just about pain relief, but its *direct* long-term impact on biological aging and all-cause mortality, beyond simply addressing the pain.

Speaker 2Exactly. While PEA is generally considered well-tolerated, and for some, an appropriate choice under medical supervision, direct evidence on its long-term effects on the epigenetic clock or all-cause mortality is still quite limited.

Speaker 1So, we have the indirect benefit of pain reduction, which we know can positively influence biological markers. But specific, robust evidence showing PEA directly *reverses* or *slows* biological aging or reduces all-cause mortality in the long term, independent of pain relief, isn't firmly established.

Speaker 2It’s a good example of distinguishing between treating a symptom that contributes to aging, and a direct anti-aging intervention. The evidence just isn’t there yet for the latter with PEA. More research is definitely needed to clarify these direct long-term effects.